IONS Ionis Pharmaceuticals Inc

-0.05 (-0.12%)
Sep 25 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 714,418
Bid Price 41.94
Ask Price 43.47
News -
Day High 43.075


52 Week Range


Day Low 41.94
Company Name Stock Ticker Symbol Market Type
Ionis Pharmaceuticals Inc IONS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -0.12% 42.66 20:00:00
Open Price Low Price High Price Close Price Prev Close
42.66 41.94 43.075 42.66 42.71
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,953 714,418 $ 42.61 $ 30,440,814 - 32.69 - 47.74
Last Trade Time Type Quantity Stock Price Currency
19:50:40 4 $ 41.95 USD

Ionis Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.11B 143.33M - 587.37M -269.72M -1.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ionis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IONS Message Board. Create One! See More Posts on IONS Message Board See More Message Board Posts

Historical IONS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week42.8343.461341.5742.73793,769-0.17-0.4%
1 Month40.3844.50539.0841.96826,9712.285.65%
3 Months41.1444.50538.2641.01896,6041.523.69%
6 Months34.1444.50533.3239.721,065,0718.5224.96%
1 Year43.0747.7432.6939.931,034,530-0.41-0.95%
3 Years48.6064.3725.0440.321,123,661-5.94-12.22%
5 Years50.5288.707525.0447.791,073,727-7.86-15.56%

Ionis Pharmaceuticals Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).